Absci Corporation
ABSIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAbsci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. At a $1.53B market cap, Absci Corporation ranks as a small-cap company within healthcare. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Market Cap
$1.53B
Beta
2.44
P/E (TTM)
—
P/E (Fwd)
-13.20
EPS (TTM)
$-0.79
EPS (Fwd)
$-0.68
ROE
-57.7%
ROA
-34.1%
Cash
$201.1M
Total Debt
$3.8M
Free CF
-$50.6M
52W Change
270.6%
Annual Financials
Cash vs Debt
Where ABSI stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ABSI finished 52.15% above its 150-day moving average ($5.81) and 70.66% above its 200-day moving average ($5.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABSI overbought or oversold?
At the September 2, 2026 close, ABSI's RSI(14) was 44.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Absci Corporation holds $201.1M in cash against $3.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$50.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.7M (2022) to $2.8M (2025), a 51% decline worth watching.
Absci Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Absci Corporation and its sector.